Brand and Other Names:Zemuron
Dosing & Uses
Dosage Forms & Strengths
- 10mg/mL (5 & 10mL vials)
Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR
Dose should be calculated based on ideal body weight
Dosage Forms & Strengths
- 10mg/mL (5 & 10mL vials)
< 3 months
- Safety and efficacy not established
3 months to 14 years
- Initial: 0.6 mg/kg IV
- Maintenance: 0.075-0.125 mg/kg IV OR
- Continuous infusion: 0.012 mcg/kg/min (IV)
> 14 years
- 0.45-0.6 mg/kg IV
- Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR
- Continuous infusion: 0.01-0.012 mg/kg/min IV
Serious - Use Alternative
Significant - Monitor Closely
Transient hypotension (1-2%)
Injection site edema
Residual muscle weakness
Allergic or idiosyncratic hypersensitivity reactions
Black Box Warnings
Lack of ventilatory support, neuromuscular disease
Other neuromuscular blocking agents
Additive/synergistic effects if administered with or following an opioid, sedative or anesthetic agent
Administer only by trained individuals familiar with its actions, characteristics, and hazard
Severe anaphylactic reactions to neuromuscular blocking agents have been reported; these reactions have, in some cases, been life threatening and fatal; because of the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken; neuromuscular cross-sensitivity with other nuromuscular blocking agents possible
Neuromuscular transmission should be monitored continuously during administration and recovery with the help of a nerve stimulator; additional doses of rocuronium or any other neuromuscular blocking agent should not be given until there is a definite response (one twitch of the train-of-four) to nerve stimulation
Use caution in patients with significant hepatic disease; if used for rapid sequence induction in patients with ascites, an increased initial dosage may be necessary to assure complete block
Some patients may experience prolonged recovery (paralysis) of neuromuscular function
Adequate ventilatory support mandatory, may experience resistance with >25% TBSA burns, may experience increased sensitivity with electrolyte disorders (hyperMg, hypoK, hypoCa)
When used with other agents, occurrence of malignant hyperthermia during anesthesia is possible even in the absence of known triggering agents; clinicians should be familiar with early signs, confirmatory diagnosis and treatment of malignant hyperthermia prior to initiating any anesthetic
Conditions associated with slower circulation time, eg, cardiovascular disease or advanced age, may be associated with a delay in onset time; since higher doses of rocuronium bromide injection produce longer duration of action, initial dosage should not be increased in these patients to reduce onset time; instead, when feasible, more time should be allowed for the drug to achieve onset of effect; geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk; effect on nursing infant not known
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Nondepolarizing skeletal muscle relaxant; cholinergic receptor antagonist; inhibits depolarization
Onset: 1-2 min
Half-Life: 60-70 min (elimination); About 2x as long in hepatic dysfunction
Duration: 30 min (0.6 mg/kg dose); 67 min (1.2 mg/kg dose)
Metabolism: Minimal hepatic metabolism
Protein binding: 30%
Vd: 0.25 L/kg
Excretion: Urine (30%); feces (70%) as active & inactive metabolites & small amounts of unchanged drug
Solution: D5W, D5/NS, LR, NS
Y-site: dexmedetomidine, fenoldopam, Hextend, milrinone
Dilute with D5W or LR to a final concentration of 0.5 or 1 mg/mL for infusion
Administer IV only
May be given undiluted as a rapid injection or via continuous infusion using an infusion pump
Refrigerate 2-8°C; do not freeze
Intact vials stored at room temp should be used within 60 d
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs